Extensive-stage small-cell lung cancer (ES-SCLC) — Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report — 2021 To 2032
Extensive-stage Small Cell Lung Cancer is characterized by a rapid doubling time and has spread widely throughout the lung, to the other lung, to lymph nodes on the other side of the chest, or other parts of the body, with high growth fraction, early development of widespread metastases, and endocrine paraneoplastic syndromes. Patients usually present shortly after developing symptoms, and the metastatic disease appears in approximately 65% of cases. Comorbidities are prevalent and constitute an increasing burden among SCLC patients, often impacting prognosis negatively. Its prevalence appears to rise with age, and the presence of multimorbidity has been linked to worse outcomes. Older age, a lower BMI, poor performance status, ES disease, and the best supportive care have all been identified as predictors of mortality in SCLC patients. As platinum-based chemotherapy (CT) has been the mainstay for the Extensive stage of Small Cell Lung Cancer (ES-SCLC), cisplatin and carboplatin are the most recommended platinum agents in combination with etoposide. The addition of immunotherapy to platinum-etoposide has resulted in a significant increase in overall survival, establishing immunotherapy as the new standard of care in ES-SCLC.
Among the total diagnosed cases, ~ 70% of patients are diagnosed with advanced, i.e., extensive stage (ES), disease.
The competitive landscape of Extensive-stage small-cell lung cancer (ES-SCLC) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.
KOLs insights of Extensive-stage small-cell lung cancer (ES-SCLC) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Extensive-stage small-cell lung cancer (ES-SCLC) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
S. No Asset Company Stage
1 Socazolimab Lee’s Pharmaceutical Limited Phase 3
2 Trilaciclib G1 Therapeutics, Inc. Phase 3
3 DS-7300a Daiichi Sankyo, Inc. Phase 2
4 BMS-986012 Bristol-Myers Squibb Phase 2
5 QL1706 Qilu Pharmaceutical Co., Ltd. Phase 2
6 AZD2811+Durvalumab AstraZeneca Phase 2
7 HLX10 Shanghai Henlius Biotech Phase 3
8 Vorolanib Xcovery Holding Company, LLC Phase 2
9 Obatoclax Gemin X Phase 1
10 irinotecan SCRI Development Innovations, LLC Phase 2
Continued
